Neuroendocrine Tumors | Topics

New Drug Application Complete for Surufatinib to Treat Pancreatic/Extra-Pancreatic NETs
May 03, 2021

Rolling submission with the FDA for surufatinib treatment in patients with pancreatic and extra-pancreatic neoendocrume tumors was completed and an expanded access program for the drug is currently underway for patients in the United States.

Adavosertib Plus Irinotecan Combination Met Efficacy End Point for Pediatric Neuroblastoma
April 13, 2021

Data presented at the virtual AACR Annual Meeting 2021 showed that a phase 2 trial examining combination treatment with adavosertib plus irinotecan met its protocol-defined efficacy end point in a cohort of pediatric patients with neuroblastoma.

Kelley Lauren Coffman, MD, on Key Takeaways from a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs
February 10, 2021

The hospitalist at Memorial Sloan Kettering Cancer Center discussed what she believes is most important for practicing oncologists to understand about a study of 177Lu-DOTATATE in well-differentiated, high-grade neuroendocrine tumors.